On the third day of ATTD 2025, five cardiometabolic-related news items have been observed from Novo Nordisk, Skye Bioscience, Terns Pharmaceuticals, Allurion Technologies, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
On the fourth and final day of JPM 2025, FENIX has provided coverage of presentations by Skye Bioscience, Esperion Therapeutics, Terns Pharmaceuticals, and Inventiva Pharma.
A series of cardiometabolic-related news items have been observed from Lilly, Novo Nordisk, Amgen, Lexicon Pharmaceuticals, Fractyl Health, Terns Pharmaceuticals, Metsera, and Gan & Lee. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Amgen, NeuroBo Pharmaceuticals, Terns Pharmaceuticals, and 89bio. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Senseonics, Abbott, Neuraly, Cytokinetics, Inventiva, and Terns. Below, FENIX provides highlights and insights for the respective news items.
On the third day of JPM 2024, FENIX has provided coverage of presentations by other CVRM companies, including Terns, Esperion, Ionis, Amarin, Embecta, and Viatris. Tomorrow is the final day of the JPM 2024 conference with presentations from Lexicon, Mannkind, and Xeris.